Emerging intrinsic therapeutic targets for metastatic breast cancer
Breast cancer is now the most common cancer worldwide, and it is also the main cause of cancer-related death in women. Survival rates for female breast cancer have significantly improved due to early diagnosis and better treatment. Nevertheless, for patients with advanced or metastatic breast cancer...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/169599 |
| _version_ | 1826110526792400896 |
|---|---|
| author | Li, Jiawei Goh, Eyleen Lay Keow He, Ji Li, Yan Fan, Zhimin Yu, Zhigang Yuan, Peng Liu, Dong-Xu |
| author2 | Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet | Lee Kong Chian School of Medicine (LKCMedicine) Li, Jiawei Goh, Eyleen Lay Keow He, Ji Li, Yan Fan, Zhimin Yu, Zhigang Yuan, Peng Liu, Dong-Xu |
| author_sort | Li, Jiawei |
| collection | NTU |
| description | Breast cancer is now the most common cancer worldwide, and it is also the main cause of cancer-related death in women. Survival rates for female breast cancer have significantly improved due to early diagnosis and better treatment. Nevertheless, for patients with advanced or metastatic breast cancer, the survival rate is still low, reflecting a need for the development of new therapies. Mechanistic insights into metastatic breast cancer have provided excellent opportunities for developing novel therapeutic strategies. Although high-throughput approaches have identified several therapeutic targets in metastatic disease, some subtypes such as triple-negative breast cancer do not yet have an apparent tumor-specific receptor or pathway to target. Therefore, exploring new druggable targets in metastatic disease is a high clinical priority. In this review, we summarize the emerging intrinsic therapeutic targets for metastatic breast cancer, including cyclin D-dependent kinases CDK4 and CDK6, the PI3K/AKT/mTOR pathway, the insulin/IGF1R pathway, the EGFR/HER family, the JAK/STAT pathway, poly(ADP-ribose) polymerases (PARP), TROP-2, Src kinases, histone modification enzymes, activated growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins. We also review the latest development in breast cancer immunotherapy. Drugs that target these molecules/pathways are either already FDA-approved or currently being tested in clinical trials. |
| first_indexed | 2024-10-01T02:35:53Z |
| format | Journal Article |
| id | ntu-10356/169599 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T02:35:53Z |
| publishDate | 2023 |
| record_format | dspace |
| spelling | ntu-10356/1695992023-07-30T15:38:14Z Emerging intrinsic therapeutic targets for metastatic breast cancer Li, Jiawei Goh, Eyleen Lay Keow He, Ji Li, Yan Fan, Zhimin Yu, Zhigang Yuan, Peng Liu, Dong-Xu Lee Kong Chian School of Medicine (LKCMedicine) Science::Medicine Breast Cancer Targeted Therapy Breast cancer is now the most common cancer worldwide, and it is also the main cause of cancer-related death in women. Survival rates for female breast cancer have significantly improved due to early diagnosis and better treatment. Nevertheless, for patients with advanced or metastatic breast cancer, the survival rate is still low, reflecting a need for the development of new therapies. Mechanistic insights into metastatic breast cancer have provided excellent opportunities for developing novel therapeutic strategies. Although high-throughput approaches have identified several therapeutic targets in metastatic disease, some subtypes such as triple-negative breast cancer do not yet have an apparent tumor-specific receptor or pathway to target. Therefore, exploring new druggable targets in metastatic disease is a high clinical priority. In this review, we summarize the emerging intrinsic therapeutic targets for metastatic breast cancer, including cyclin D-dependent kinases CDK4 and CDK6, the PI3K/AKT/mTOR pathway, the insulin/IGF1R pathway, the EGFR/HER family, the JAK/STAT pathway, poly(ADP-ribose) polymerases (PARP), TROP-2, Src kinases, histone modification enzymes, activated growth factor receptors, androgen receptors, breast cancer stem cells, matrix metalloproteinases, and immune checkpoint proteins. We also review the latest development in breast cancer immunotherapy. Drugs that target these molecules/pathways are either already FDA-approved or currently being tested in clinical trials. Published version 2023-07-25T07:46:01Z 2023-07-25T07:46:01Z 2023 Journal Article Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P. & Liu, D. (2023). Emerging intrinsic therapeutic targets for metastatic breast cancer. Biology, 12(5), 697-. https://dx.doi.org/10.3390/biology12050697 2079-7737 https://hdl.handle.net/10356/169599 10.3390/biology12050697 37237509 2-s2.0-85160240720 5 12 697 en Biology © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). application/pdf |
| spellingShingle | Science::Medicine Breast Cancer Targeted Therapy Li, Jiawei Goh, Eyleen Lay Keow He, Ji Li, Yan Fan, Zhimin Yu, Zhigang Yuan, Peng Liu, Dong-Xu Emerging intrinsic therapeutic targets for metastatic breast cancer |
| title | Emerging intrinsic therapeutic targets for metastatic breast cancer |
| title_full | Emerging intrinsic therapeutic targets for metastatic breast cancer |
| title_fullStr | Emerging intrinsic therapeutic targets for metastatic breast cancer |
| title_full_unstemmed | Emerging intrinsic therapeutic targets for metastatic breast cancer |
| title_short | Emerging intrinsic therapeutic targets for metastatic breast cancer |
| title_sort | emerging intrinsic therapeutic targets for metastatic breast cancer |
| topic | Science::Medicine Breast Cancer Targeted Therapy |
| url | https://hdl.handle.net/10356/169599 |
| work_keys_str_mv | AT lijiawei emergingintrinsictherapeutictargetsformetastaticbreastcancer AT goheyleenlaykeow emergingintrinsictherapeutictargetsformetastaticbreastcancer AT heji emergingintrinsictherapeutictargetsformetastaticbreastcancer AT liyan emergingintrinsictherapeutictargetsformetastaticbreastcancer AT fanzhimin emergingintrinsictherapeutictargetsformetastaticbreastcancer AT yuzhigang emergingintrinsictherapeutictargetsformetastaticbreastcancer AT yuanpeng emergingintrinsictherapeutictargetsformetastaticbreastcancer AT liudongxu emergingintrinsictherapeutictargetsformetastaticbreastcancer |